Trials / Completed
CompletedNCT00860600
Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients
The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- PhytoHealth Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a phase II multi-center, randomized, open-label study with two parallel study groups to evaluate the efficacy and safety of PG2 in ITP patients.
Detailed description
The primary objective of this exploratory study is to evaluate the efficacy of PG2 in raising the platelet counts in ITP patients using two dosing schedules. The secondary objective is to determine the safety of PG2 treatment among these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PG2 | 500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2009-03-12
- Last updated
- 2025-06-04
Locations
4 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00860600. Inclusion in this directory is not an endorsement.